Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A.

Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19.

PMID:
31427438
2.

Prevalence of calcium pyrophosphate deposition disease in a cohort of patients diagnosed with seronegative rheumatoid arthritis.

Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T.

Clin Exp Rheumatol. 2020 Jan-Feb;38(1):99-106. Epub 2019 May 22.

3.

Does early seronegative arthritis develop into rheumatoid arthritis? A 10-year observational study.

Paalanen K, Rannio K, Rannio T, Asikainen J, Hannonen P, Sokka T.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):37-43. Epub 2018 Jun 7.

4.

Survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) in usual rheumatology care.

Nikiphorou E, Hannonen P, Asikainen J, Borodina J, Kokko A, Paalanen K, Rannio T, Sokka T.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):55-59. Epub 2018 Jun 7.

PMID:
29998827
5.

A cross-sectional study of vitamin D levels in a large cohort of patients with rheumatic diseases.

Nikiphorou E, Uksila J, Sokka T.

Clin Rheumatol. 2018 Mar;37(3):803-810. doi: 10.1007/s10067-017-3870-8. Epub 2017 Nov 7.

6.

Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.

Khan NA, Spencer HJ, Nikiphorou E, Naranjo A, Alten R, Chirieac RM, Drosos AA, Géher P, Inanc N, Kerzberg E, Ancuta CM, Müller R, Ørnbjerg L, Sokka T.

Rheumatology (Oxford). 2017 Aug 1;56(8):1395-1400. doi: 10.1093/rheumatology/kex076.

PMID:
28575509
7.

Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis.

Pirilä L, Sokka T, Kauppi MJ, Rantalaiho VM, Mervaala E, Puolakka K.

Ann Rheum Dis. 2017 Dec;76(12):e49. doi: 10.1136/annrheumdis-2017-211505. Epub 2017 Apr 27. No abstract available.

PMID:
28450311
8.

Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.

Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.

Scand J Rheumatol. 2017 Nov;46(6):425-431. doi: 10.1080/03009742.2016.1266029. Epub 2017 Apr 3.

PMID:
28367663
9.

The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.

Nikiphorou E, Galloway J, van Riel P, Yazici Y, Haugeberg G, Ostor A, Gogus F, Kauppi M, Sokka T; QUEST-RA.

Clin Exp Rheumatol. 2017 May-Jun;35(3):477-483. Epub 2017 Jan 27.

PMID:
28134086
10.

Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study.

Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, Uutela T, Puurtinen-Vilkki M, Arstila L, Blom M, Sokka T, Nordström D.

Semin Arthritis Rheum. 2017 Jun;46(6):732-739. doi: 10.1016/j.semarthrit.2016.09.005. Epub 2016 Sep 16.

PMID:
28010883
12.

Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.

Aaltonen KJ, Joensuu JT, Pirilä L, Kauppi M, Uutela T, Varjolahti-Lehtinen T, Yli-Kerttula T, Isomäki P, Nordström D, Sokka T.

Scand J Rheumatol. 2017 Sep;46(5):359-363. doi: 10.1080/03009742.2016.1234641. Epub 2016 Dec 8.

PMID:
27931158
13.

Go, go, GoTreatIT!

Sokka T.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S91-S95. Epub 2016 Oct 19. Review.

14.

Delivering a one-stop, integrated, and patient-centered service for patients with rheumatic diseases.

Väre P, Nikiphorou E, Hannonen P, Sokka T.

SAGE Open Med. 2016 Jun 14;4:2050312116654404. doi: 10.1177/2050312116654404. eCollection 2016.

15.

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.

Rheumatology (Oxford). 2016 Oct;55(10):1803-11. doi: 10.1093/rheumatology/kew264. Epub 2016 Jun 27.

PMID:
27354689
16.

Long-term outcomes of destructive seronegative (rheumatoid) arthritis - description of four clinical cases.

Nikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T.

BMC Musculoskelet Disord. 2016 Jun 3;17:246. doi: 10.1186/s12891-016-1067-y.

17.

A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.

Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):694-7. Epub 2016 May 19.

PMID:
27213997
18.

Is long-term radiographic joint damage different between men and women? Prospective longitudinal data analysis of four early RA cohorts with greater than 15 years follow-up.

Asikainen J, Nikiphorou E, Kaarela K, Lindqvist E, Häkkinen A, Kautiainen H, Hannonen P, Rannio T, Sokka T.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):641-5. Epub 2016 Apr 28.

19.

Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.

Rannio T, Asikainen J, Kokko A, Hannonen P, Sokka T.

J Rheumatol. 2016 Apr;43(4):699-706. doi: 10.3899/jrheum.141480. Epub 2016 Feb 15.

PMID:
26879355
20.

Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.

Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, Sokka T.

Expert Opin Biol Ther. 2015;15(12):1677-83. doi: 10.1517/14712598.2015.1103733. Epub 2015 Nov 7.

PMID:
26549204
21.

Rheumatoid Arthritis in the 21st Century: Treatment Patterns and Disease Activity States.

Nikiphorou E, Rannio T, Sokka T.

J Rheumatol. 2015 Sep;42(9):1542-4. doi: 10.3899/jrheum.150615. No abstract available.

PMID:
26330124
22.
23.

[Update on Current Care Guidelines: Ectopic pregnancy].

Mäkinen J, Töyli M, Niemimaa M, Kulju P, Sokka T, Vuorela P; Päivitystiivistelmä.

Duodecim. 2015;131(1):90-1. Finnish.

PMID:
26245062
24.

Utility of a novel inflammatory marker, GlycA, for assessment of rheumatoid arthritis disease activity and coronary atherosclerosis.

Ormseth MJ, Chung CP, Oeser AM, Connelly MA, Sokka T, Raggi P, Solus JF, Otvos JD, Stein CM.

Arthritis Res Ther. 2015 May 9;17:117. doi: 10.1186/s13075-015-0646-x.

25.

A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.

Michelsen B, Fiane R, Diamantopoulos AP, Soldal DM, Hansen IJ, Sokka T, Kavanaugh A, Haugeberg G.

PLoS One. 2015 Apr 8;10(4):e0123582. doi: 10.1371/journal.pone.0123582. eCollection 2015.

26.

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.

Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D.

J Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.

PMID:
25593230
27.

How do we classify rheumatoid arthritis in established disease--can we apply the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria?

Humphreys JH, Verstappen SM, Scire CA, Uhlig T, Fautrel B, Sokka T, Symmons DP.

J Rheumatol. 2014 Dec;41(12):2347-51. doi: 10.3899/jrheum.141443. No abstract available.

PMID:
25452179
28.

The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.

Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW, Henrohn D, Rasker JJ, Kauppi MJ, Lang HC, Mota LM, Aggarwal A, Yamanaka H, Badsha H, Gossec L, Cutolo M, Ferraccioli G, Gremese E, Bong Lee E, Inanc N, Direskeneli H, Taylor P, Huisman M, Alten R, Pohl C, Oyoo O, Stropuviene S, Drosos AA, Kerzberg E, Ancuta C, Mofti A, Bergman M, Detert J, Selim ZI, Abda EA, Rexhepi B, Sokka T.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20.

PMID:
25327997
30.

The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis.

Inanc N, Yilmaz-Oner S, Can M, Sokka T, Direskeneli H.

J Rheumatol. 2014 Sep;41(9):1755-60. doi: 10.3899/jrheum.131171. Epub 2014 Aug 1.

PMID:
25086073
31.

Smoking cessation advice by rheumatologists: results of an international survey.

Naranjo A, Khan NA, Cutolo M, Lee SS, Lazovskis J, Laas K, Pandya S, Sokka T; QUEST-RA group.

Rheumatology (Oxford). 2014 Oct;53(10):1825-9. doi: 10.1093/rheumatology/keu213. Epub 2014 May 19.

PMID:
24840678
32.

A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.

Aaltonen KJ, Sokka T, Möttönen T, Korpela M, Komulainen R, Uusitalo T, Salomaa S, Uutela T, Valleala H, Rami Study Group.

Scand J Rheumatol. 2014;43(4):286-90. doi: 10.3109/03009742.2013.876512. Epub 2014 Mar 24.

PMID:
24654994
33.

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Putrik P, Ramiro S, Kvien TK, Sokka T, Uhlig T, Boonen A; Equity in Clinical Eligibility Criteria for RA treatment Working Group.

Ann Rheum Dis. 2014 Nov;73(11):2010-21. doi: 10.1136/annrheumdis-2013-203819. Epub 2013 Aug 12.

PMID:
23940213
34.

Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study.

Aaltonen KJ, Virkki LM, Jämsen E, Sokka T, Konttinen YT, Peltomaa R, Tuompo R, Yli-Kerttula T, Kortelainen S, Ahokas-Tuohinto P, Blom M, Nordström DC.

Semin Arthritis Rheum. 2013 Aug;43(1):55-62. doi: 10.1016/j.semarthrit.2013.01.002. Epub 2013 Mar 5.

PMID:
23481417
35.

Inequities in access to biologic and synthetic DMARDs across 46 European countries.

Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group ‘Equity in access to treatment of rheumatoid arthritis in Europe’.

Ann Rheum Dis. 2014 Jan;73(1):198-206. doi: 10.1136/annrheumdis-2012-202603. Epub 2013 Mar 6.

PMID:
23467636
36.

'Rheumatologist go home!' Coming up next?

Uhlig T, Sokka T.

Ann Rheum Dis. 2013 Jul;72(7):1111-2. doi: 10.1136/annrheumdis-2012-202787. Epub 2013 Feb 20. No abstract available.

PMID:
23426042
37.

Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics.

Sokka T, Haugeberg G, Asikainen J, Widding Hansen IJ, Kokko A, Rannio T, Soldal DM, Hannonen P.

Clin Exp Rheumatol. 2013 May-Jun;31(3):409-14. Epub 2013 Feb 15.

PMID:
23415074
38.

Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): lessons from QUEST RA.

Putrik P, Sokka T, Ramiro S, Boonen A.

Best Pract Res Clin Rheumatol. 2012 Oct;26(5):705-20. doi: 10.1016/j.berh.2012.07.011. Review.

PMID:
23218433
39.
40.

Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?

Mäkinen H, Kaarela K, Huhtala H, Hannonen PJ, Korpela M, Sokka T.

Ann Rheum Dis. 2013 May;72(5):745-7. doi: 10.1136/annrheumdis-2012-201943. Epub 2012 Nov 21.

PMID:
23172747
41.

Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis.

Sokka T, Rannio T, Khan NA.

Rheum Dis Clin North Am. 2012 May;38(2):299-310. doi: 10.1016/j.rdc.2012.04.005. Epub 2012 May 25. Review.

PMID:
22819085
42.

Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?

Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C, Cazzato M, Géher P, Gossec L, Henrohn D, Hetland ML, Inanc N, Jacobs JW, Kerzberg E, Majdan M, Oyoo O, Peredo-Wende RA, Selim ZI, Skopouli FN, Sulli A, Hørslev-Petersen K, Taylor PC, Sokka T; QUEST-RA group.

Ann Rheum Dis. 2012 Dec;71(12):1942-9. doi: 10.1136/annrheumdis-2011-201142. Epub 2012 Apr 24.

43.

The impact of coping strategies on mental and physical well-being in patients with rheumatoid arthritis.

Englbrecht M, Gossec L, DeLongis A, Scholte-Voshaar M, Sokka T, Kvien TK, Schett G.

Semin Arthritis Rheum. 2012 Feb;41(4):545-55. doi: 10.1016/j.semarthrit.2011.07.009.

PMID:
22340997
44.

Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years.

Pincus T, Castrejón I, Sokka T.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S130-8. Epub 2011 Oct 22.

PMID:
22018199
45.

Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity.

Khan NA, Spencer HJ, Abda E, Aggarwal A, Alten R, Ancuta C, Andersone D, Bergman M, Craig-Muller J, Detert J, Georgescu L, Gossec L, Hamoud H, Jacobs JW, Laurindo IM, Majdan M, Naranjo A, Pandya S, Pohl C, Schett G, Selim ZI, Toloza S, Yamanaka H, Sokka T.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):206-14. doi: 10.1002/acr.20685.

46.

Declining needs for total joint replacements for rheumatoid arthritis.

Khan NA, Sokka T.

Arthritis Res Ther. 2011;13(5):130. doi: 10.1186/ar3478. Epub 2011 Oct 19.

48.

Chronic back pain in patients with rheumatoid arthritis and in a control population: prevalence and disability--a 5-year follow-up.

Neva MH, Häkkinen A, Isomäki P, Sokka T.

Rheumatology (Oxford). 2011 Sep;50(9):1635-9. doi: 10.1093/rheumatology/ker173. Epub 2011 May 10.

PMID:
21558326
49.

Morning stiffness and other patient-reported outcomes of rheumatoid arthritis in clinical practice.

Sokka T.

Scand J Rheumatol Suppl. 2011;125:23-7. doi: 10.3109/03009742.2011.566437.

PMID:
21529307
50.

Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative.

Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, Gogus F, Heiberg T, Hernandez C, Kirwan JR, Mola EM, Cerinic MM, Otsa K, Schett G, Scholte-Voshaar M, Sokka T, von Krause G, Wells GA, Kvien TK.

Ann Rheum Dis. 2011 Jun;70(6):935-42. doi: 10.1136/ard.2010.142901.

PMID:
21540201

Supplemental Content

Support Center